Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Prothena Co. plc (NASDAQ:PRTA – Get Rating) CFO Tran Nguyen sold 10,000 shares of Prothena stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $55.53, for a total value of $555,300.00. Following the sale, the chief financial officer now owns 3,200 shares in the company, valued at approximately $177,696. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Tran Nguyen also recently made the following trade(s):
- On Wednesday, December 21st, Tran Nguyen sold 10,000 shares of Prothena stock. The stock was sold at an average price of $58.97, for a total value of $589,700.00.
- On Wednesday, November 23rd, Tran Nguyen sold 10,000 shares of Prothena stock. The stock was sold at an average price of $61.09, for a total value of $610,900.00.
Prothena Trading Up 1.1 %
Shares of NASDAQ:PRTA traded up $0.61 during trading on Friday, hitting $54.56. 421,425 shares of the stock were exchanged, compared to its average volume of 637,340. The company has a fifty day moving average price of $58.16 and a two-hundred day moving average price of $46.23. The company has a market cap of $2.64 billion, a PE ratio of -16.34 and a beta of 0.52. Prothena Co. plc has a 12-month low of $21.06 and a 12-month high of $66.47.
Prothena (NASDAQ:PRTA – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.66). The firm had revenue of $1.52 million for the quarter, compared to analysts’ expectations of $26.74 million. Prothena had a negative return on equity of 36.46% and a negative net margin of 3,036.03%. Equities research analysts anticipate that Prothena Co. plc will post -2.86 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Prothena
Several institutional investors have recently modified their holdings of the company. ProShare Advisors LLC boosted its stake in shares of Prothena by 3.0% during the 3rd quarter. ProShare Advisors LLC now owns 7,858 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 228 shares in the last quarter. Credit Suisse AG raised its position in shares of Prothena by 1.3% during the 2nd quarter. Credit Suisse AG now owns 27,724 shares of the biotechnology company’s stock worth $753,000 after purchasing an additional 369 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Prothena during the 3rd quarter worth approximately $27,000. Lazard Asset Management LLC raised its position in shares of Prothena by 61.1% during the 1st quarter. Lazard Asset Management LLC now owns 1,733 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 657 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its position in shares of Prothena by 22.7% during the 2nd quarter. Virtus ETF Advisers LLC now owns 4,523 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 837 shares during the last quarter. Hedge funds and other institutional investors own 91.72% of the company’s stock.
Analysts Set New Price Targets
A number of research firms recently issued reports on PRTA. Oppenheimer raised their price target on Prothena from $110.00 to $120.00 in a report on Tuesday, November 15th. JMP Securities raised their price target on Prothena from $50.00 to $81.00 in a report on Wednesday, September 28th. Citigroup lifted their price objective on Prothena from $65.00 to $71.00 and gave the company a “buy” rating in a report on Monday, October 24th. Cantor Fitzgerald lifted their price objective on Prothena from $91.00 to $98.00 and gave the company an “overweight” rating in a report on Wednesday, December 21st. Finally, StockNews.com assumed coverage on Prothena in a report on Wednesday, October 12th. They issued a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $81.67.
About Prothena
(Get Rating)
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Articles
- Get a free copy of the StockNews.com research report on Prothena (PRTA)
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prothena, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Prothena wasn’t on the list.
While Prothena currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise.
Enter your email address below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
